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Gene-mutations at the 6-thioguanine locus, in Hbroblast like-
cells rapidly proliferating on the inside of rat subcutaneous
air pouches were analysed (Granuloma Pouch Assay). Target
cells were exposed directly by injection into the air pouch,
or systemicaliy by oral or intraperitoneal administration to
three hepatocarcinogens aflatoxin B,, 2-acetyIaminofluorene
(2-AAF) and vinylchloride. In addition ethylnitrosourea
(ENU) was used as a positive control, and 2-aminofluorene
to characterize the pharmacokinetic behaviour of 2-AAF.
When administered directly, all chemicals except 2-AAF
induced a dose-dependent increase in gene-mutation
frequencies. However, 2-AAF was mutagenic after oral
administration. The highest inducible mutation frequencies
found with the hepatocarcinogens were 8 to 10 times the
spontaneous mutation frequency, but only ~ 10% of that
found with the control mutagen ENU. The known enzymic
activation capacity of the granulation tissue, and the
mutagenic activity of other chemicals in this system already
reported, suggest that after direct exposure, the prostaglandin
H synthetase pathway or lipoxygenases are involved in the
activation of the hepatotoxins to gene mutation inducing
species in vivo. 2-AAF seems to be converted via stable
intermediates to the ultimate mutagenic species in the extra-
hepatic target tissues.
Introduction
Risk evaluation of chemicals must take into account their gene-
mutation inducing capacity in extrahepatic tissues in vivo. Not
only because the first interaction of a chemical with an organism
occurs at extrahepatic tissues (e.g. via inhalation, skin contamina-
tion or ingestion) but also, because after systemic exposure stable
intermediates may be formed for instance in the liver, which are
mutagenically active in extrahepatic tissues (33). The analysis
of gene-mutations is important because a chemical's gene-
mutation inducing activity does not necessarily correlate with its
clastogenic activity e.g. determined in bone marrow.
Chemicals often not considered hazardous in extrahepatic
tissues include those known to be activated by cytochrome P-450
dependent mono-oxygenases. In tissues with low or zero mono-
oxygenase activity, however, the peroxidative activation of
xenobiotics might provide an alternative activation pathway. In
rats, this pathway has been reported to play a role in the lung,
renal medulla, forestomach, bone marrow, urinary tract and
granulation tissue (28). Its role in the conversion of chemicals
* Abbreviations: AFB|, aflatoxin B,; 2-AAF, acetylaminofluorene; 2-AF,
2-aminofluorene; VCM, vinylchloride, monomeric; ENU, ethylnitrosourea; FCS,
fetal calf serum; IQ, 2-amino-3-methylimidazo[4,5-y]-<iuinoline; BP, benzo[a]-
pyrene; HGPRT, hypoxanthine-guanine phosphoribosyl transferase.
to gene-mutation inducing metabolites in vivo needs to be
elucidated.
The method of choice for studying this problem is the
Granuloma Pouch Assay. In this animal model, among other
genetic endpoints, gene-mutations can be detected in individual,
in vivo exposed cells (34). Target cells can be exposed directly
to test compounds including gaseous chemicals. This feature is
a unique characteristic of this assay not present in other
established in vivo mutagenicity tests with extrahepatic tissue such
as blood cells (41), bone marrow cells (31,46), embryonic cells
(17) or germ cells (14).
In the Granuloma Pouch Assay, no cytochrome P-450
dependent mono-oxygenases have yet been detected in the target
tissue. The prostaglandin H synthetase (28) and the lipid-
peroxidation dependent pathways (29), however have been
identified. Xenobiotics might serve as reducing factors during
the peroxidative reduction of prostaglandins (PGG2—PGH2)
(42). In vitro, it has been shown that a number of chemicals can
be cooxidized by this pathway into reactive intermediates (15)
or mutagenic metabolites (45).
Three of the five chemicals tested, aflatoxin B, (AFB^),
2-acetylaminofluorene (2-AAF) and gaseous monomeric vinyl-
chloride (VCM) were carcinogenic predominantly in liver. VCM
induces angiosarcoma in laboratory animals and man (16,18).
In vitro, AFB] and aromatic amines are known substrates for
the PHS pathway (6,7). 2-Aminofluorene (2-AF) was included
in this study to assist in the elucidation of the pharmacokinetics
of 2-AAF, and ethylnitrosourea (ENU) was used as a positive
control.
Thus, by comparing the mutagenic activity detected after
systemic application and after direct exposure, the
pharmacokinetic behaviour of a mutagenic species can be
characterized (36).
Materials and methods
Animals and target celts
Randomly bred male albino Sprague - Dawley rats (SIV 50 Ivanovas Kisslegg,
FRG, 230-260 g, 54 ± 4 days old) were used. Aliquots of 25 ml of germ free
air were injected subcutaneously at the midpoint of the scapular area on the back
of the animals. This induced sufficient growth of cells forming the target tissue
at the inside wall of the air pouch: additional application of croton oil would not
have produced more fibroblast-like cells capable of growing in vitro (34,35). The
test compound was administered at the height of proliferative activity (48 h after
pouch formation), either intraperitoneally, directly into the air pouch or by gavage.
Two days later, the animals were sacrificed using CO2. The granulation tissues
were removed by aseptic dissection. Red blood cells were lyzed by washing the
tissue for 10 s in sterile distilled water. The tissue was then minced in 1 ml
Dulbecco's phosphate buffer (PBS, pH 7.4), and subjected to enzymic dissociation
[ 10 ml PBS containing collagenase Type I (600 Mandl-U) and Dispase II (8U),
stirring for 45 min at 35°C]. Subsequently, the resultant suspension was filtered
through two layers of Kodak lens paper: the filtrate, consisting of tissue fragments,
was then minced and incubated for a second time as described above. Finally,
the two cell suspensions were pooled, centrifuged for 5 min at 134 g and
resuspended in culture medium [Dulbecco's modified Eagle medium, 10% fetal
calf serum (FCS), 50 /tg/ml Gentamycin]. The viability of cells, as determined
by the trypan blue exclusion test was above 95%, except at the highest exposure
levels, where the number of cells without damaged membranes dropped below
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Table I. Mutation induction in vivo at the 6-TG locus in fibroblast-like cells of the subcutaneous granulation tissue in rats
Chemical exposure
level
Cloning efficiency
1 CE
(mean ± SD)
II CE
(mean ± SD)
No of clone
forming cells
tested
(x 106)
Mutant frequency
(mean ± SD)
no-6)
No. of
animals
tested
Control I 14.5 ± 4.6 64.9 ± 14.4 6.800 2.48 ± 3.69
ENU
Application into the air pouch:
0.06 mg/GP
0.25 mg/GP
0.33 mg/GP
1.33 mg/GP
Intraperitonal application:
20 mg/kg i.p.
80 mg/kg i.p.
Aflatoxin Bj
20.8
18.5
4.3
12.9
25.5 ± 6.0
20.6 ± 2.9
75.5
92.7
12.0
89.0
59.1 ± 16.8
67.3 ± 19.0
0.906
1.112
0.144
1.068
2.097
2.422
Application into the air pouch:
10 ^g/GP 10.4
20 ^g/GP 13.4 ± 1.0
40 /tg/GP 14.9 ± 6.2
60 ^g/GP 12.7
Vinylchloride
Application into the air pouch:
0.5 mg/GP 12.4 ± 2.2
1.0 mg/GP 13.1 ± 7.6
2.0 mg/GP 15.4 ± 3.0
4.0 mg/GP 19.6
Mutation frequencies in subpopulations:
Total cell population
Control 7.6 ± 0.1
VCM 2.0 mg/GP 18.5
Fraction (IB+2)
Control 18.5
VCM 2.0 mg/GP 23.6 ± 4.8
Control 11
2-Acetylaminofluorene
Application into the air pouch:
0.8 mg/GP
1.6 mg/GP
3.2 mg/GP
14 mg/GP
20 mg/GP
Oral application:
20 mg/kg p.o.
40 mg/kg p.o.
60 mg/kg p.o.
80 mg/kg p.o.
120 mg/kg p.o.
16.9
16.9
13.5
16.8
12.0
15.4
13.8
14.9
19.0
18.8
17.0
±
±
±
±
±
4.4
8.5
6.0
6.6
7.4
66.3
67.5
49.9
71.2
±
±
5
19
.1
.8
0.796
3.107
4.830
1.708
62.0 ± 5.6
58.1 ± 9.1
51.7 ± 7.4
50.1
55.5
50.0
50.0
48.8
6.2
9.0
± 12.3
68.9 ± 17.6
72.5
73.8 ± 3.9
64.2
59.7
22.7
55.8
53.2 ± 17.1
65.6 ± 13.0
63.3 ± 13.2
65.9
Pretreatment 2 X intraperitoneally, subsequently 1 x oral application:
3 x 20 mg/kg 28.1 88.6
3 x 40 mg/kg 20.9 ± 3.5 75.8 ±
3 x 60 mg/kg 16.7 ± 2.7 71.7 ±
3 x 80 mg/kg 9.6 89.4
13.4
17.2
2-Aminofluorene
Application into the air pouch:
0.1 mg/GP
0.2 mg/GP
22.6
13.3
48.2
44.5
2.645
2.092
2.982
1.050
1.818
1.794
1.200
1.632
12.202
1.145
2.505
1.260
0.716
0.272
1.163
2.343
3.148
1.986
1.580
2.037
3.248
3.248
1.714
0.578
0.225
27.603
111.50"
340.20"
148.80"
60.7
280.9
±
±
15.3
148.3
1.26
12.74 ±
21.71 ±
8.75"
12.65"
13.03"
1
4
9
2
4.20
17.04
10.86
9.55"
±
±
±
6.40"
7.89"
11.30"
4
3
5
2
0
18 10 ±
0.70
28.50 ±
2.97 ±
1.41
7.39 ±
0.72
0
0
5.51
11.51 ±
16.06 ±
12.46 ±
7.60"
8.16"
21.09 ±
35.52 ±
11.68"
7.60"-b
10.20"b
3.36
3.03"
11.10"
12.67"
13.19"
17.01"
29.10"
3
3
2
3
15
2
3
2
1
1
2
4
4
4
2
2
4
4
2
3.42
0
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Table I. continued
Chemical exposure
level
0.4 mg/GP
0.8 mg/GP
1.6 mg/GP
3.2 mg/GP
Oral application:
15 mg/kg p.o.
30 mg/kg p.o.
60 mg/kg p.o.
200 mg/kg p.o.
Cloning efficiency
I CE
(mean ± SD)
12.5
18.1
6.6
11.8
13.2
19.2
II CE
(mean
46.2
83.5
66.3
34.6
51.5
40.5
lethal
No. of clone
forming cells
_i_ cryi tested
(x 106)
0.850
2.004
1.591
no growth in vitro
0.801
1.236
0.122
within 48 h after application
Mutant frequency
(mean ± SD)
27.54a
36.95a
9.38a
2.00
4.05
0
No. of
animals
tested
2
2
2
1
2
2
1
1
"Significantly different from the corresponding control values at P < 0.05 one sided, according to Kastenbaum and Bowman (23).
bSignificantly different in pairs.
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Fig. 1. Exposure-response curves of gene-mutation frequencies (6-TGr) after oral application (p.o.), application into the air pouch (GP), or after intraperitoneal
pretreatment (2 x i.p.).
90%. On average, 20.5
per rat.
7.6 x 106 (N = 26) nucleated cells were collected
Chemicals and exposure
Chemicals were injected into the air pouch or administered by gavage in a final
volume of 1 ml. AFB, (Sigma, St Louis, MO, puriss. >99.5% analyzed by GC)
was dissolved in ethanol. The concentrations were determined spectrophoto-
metrically at 360 nm before dilution (EtOH <4%, v/v) with culture medium
without FCS. 2AAF (Fluka, Buchs, Switzerland, puriss. 98% UV) was dissolved
in polyoxyethylated castor oil (Mugolfen 620, GAF Cooperation, Zug,
Switzerland). The exposure level of VCM (Fluka, Buchs SG, Switzerland) was
analyzed by gas chromatography (2 m glass column, inner diameter 2 mm,
Chromabsorb GAW, 80/100 mesh, 5% SP-100, T injection 200°C, T column
21°C, T detector 300°C, detector FID, carrier gas N2, 46 cm'/min), samples
being taken from the pouch immediately after administration. 2-AF was dissolved
in ethanol and diluted in culture medium without FCS. ENU was dissolved in
0.9% saline solution. Administration routes, sequence and exposure levels are
summarized in Table I.
Cell culture and selection of mutants resistant to 6-thioguanine
3 x 103 (103 cells/100 mm dish) of the freshly isolated cells were tested for their
primary cloning efficiency 0 CE) after incubation for 7 days. 106 cells were
cultured for 3 days in a 150 mm dish, trypsinized and incubated for another 3 days.
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Fig. 2. Relative decrease of monomeric vinylchloride in the subcutaneous
air pouch as a function of time after injection (100% = 2 mg/GP).
After this 6-day expression period, the cells were harvested and distributed into
12 dishes (105 cells/100 mm dish) containing the selective medium (15 ^g
6-thioguanine/ml medium, 10% dialyzed FCS) and for the determination of the
secondary cloning efficiency (II CE) three dishes (300 cells/100 mm dish) without
the selective agent. After 8 days, clones were stained and counted: mutation
frequencies were expressed as the number of mutants per 106 colony forming
cells (Table I).
Results
Spontaneously arising mutations at the 6-thioguanine resistance
locus in fibroblast like granulation tissue cells from animals only
treated with the solvents were analysed: half of the control animals
received 1 ml 2% ethanol in culture media, the others 1 ml
mugolfen 620 injected into the air pouch. These controls were
analysed concurrently with the test series. In Table I, control
I represents concurrent control during the analyses of the first
three chemicals and control II is the mean of the whole series.
After both direct and systemic administration, the control
mutagen ENU induced mutation frequencies more than 100
greater than the spontaneous level. These increased mutation
frequencies are comparable to those induced by other agents, such
as Af-methyl-N'-nitro-iV-nitrosoguanidine (32), procarbazine (33)
and aristolochic acid (34) in the Granuloma Pouch Assay.
Mutation frequencies determined after direct exposure of the
target tissue to AFBi, VCM and 2-AF, and after oral admin-
istration of 2-AAF (Table I; Figure 1), ranged from 5 to 10 times
the spontaneous mutation frequency. The highest inducible
mutation frequencies were 6-10% of those of the control
mutagen.
No significant increase in mutagenic activity was detected after
oral administration of AFB| (at levels of 0.23 and 0.93 mg/kg,
one animal each, data not shown) or of 2-AF (Table I, Figure 1).
In the case of VCM, no clear dose—response relationship was
established. Two possible reasons were further investigated.
Firstly the presence over a given time interval of a non linear
concentration of reactive monomers; secondly, that only a limited
number of sensitive target cells is available in the tissue, for
instance a (hypothetical) subpopulation in which phospholipid
turnover can be specifically stimulated. VCM concentration was
determined in samples taken from the air pouch at different time
intervals after the initial VCM application (Figure 2). Mutation
frequencies were determined in a subfraction of the freshly
isolated cells separated by counterflow centrifugation (Beckman,
J2-21 centrifuge, JE-6B elutriation system, Palo Alto, CA, USA;
elutriation conditions: 4°C, Hanks balanced salt solution,
1500 r.p.m., 4 .3-7 .8 ml/min, theoretical size of 12-20 /tin
diameter) and representing 27.9% ± 3.6 (N = 4) of the total
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Fig. 3. Highest induced mutation frequencies at the 6-TG locus reported in
the Granuloma Pouch Assay after single direct exposure of target cells. •
Data from Maier etai, 1980 and * Rademacher etal., 1987.
cell population. Compared to the major fraction, the clone
forming capacity of the separated cells was enhanced (Table I),
their aldrin epoxidase activity increased by 30—90% (19) and
the highest inducible mutation frequency doubled (Table I).
2-AAF was mutagenic only after oral administration: pretreat-
ment of the animals (two i.p. administrations) increased the total
number of mutants compared with p.o. administration alone
(Table I, Figure 1).
Discussion
In the Granuloma Pouch Assay, the initial interaction of the test
compound with DNA and the development of this primary lesion
into a stable condition occur in vivo, whereas the expression of
the mutant phenotype is facilitated by cell divisions in vitro: this
restricts the analysis to cells with a high proliferative capacity,
and therefore with a high probability of developing further into
neoplastic cells.
At the HGPRT locus it is possible to detect base pair sub-
stitutions and small deletions which include the 6-TGr-locus; as
has been shown both after irradiation and exposure to a number
of different chemicals (22,23). Functional, multilocus deletion
mutants, however, cannot be detected efficiently (48,49); this
is especially true for chemicals which initiate DNA-strand breaks.
This might offer an explanation for the relatively low response,
compared with the control mutagen of the chemicals tested.
Alternatively, these low mutation frequencies could be a
consequence of a limited metabolic competence of the target
tissue. The mutagenic activity detected after direct exposure of
the granulation tissue suggests that pathways of cooxidation such
as the prostaglandin synthetase (PHS) are involved. The following
facts favour this interpretation: (i) the absence of cytochrome
P-450-dependent mono-oxygenases in the granulation tissue (27),
(ii) the oxidative conversion of aldrin to dieldrin mediated by
the prostaglandin synthetase pathway (28) and by lipid per-
oxidation (29) in these target cells, (iii) the production of prosta-
glandin (PGE2) by granulation tissue cells ex vivo (27), and
(iv) the increased synthesis of prostaglandins and other hydroxy
fatty acids which parallels tissue growth (9) during granuloma
development in rats. However, the fact that prostaglandins
influence cell proliferation (11) and DNA replication (40) in
mammalian cells, and are involved in inflammatory processes
in the rat air pouch (43) and in the growth of tumours (30),
obstructed a direct investigation of the pathways involved in
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metabolic activation. The use of specific inhibitors of the cyclo-
oxygenase (e.g. indomethacin) will, therefore, also affect
processes of mutation fixation. As a consequence, the modified
mutation frequencies cannot be attributed unambiguously either
to an initiation (mutation) or to a fixation (proliferation) step.
The mutagenic activity of AFB, after direct exposure was
unexpected. However, the involvement of PHS metabolism in
the mutagenicity of AFB! in vitro has been reported: DNA
binding of AFB, is inhibited by indomethacin (2), and in
bacterial tests AFB[ is covalently bound as an epoxide to DNA
when incubated with ram seminal vesicle, a source of PHS (6).
In vivo, a low incidence of micronucleated polychromatophilic
erythrocytes is found in extrahepatic tissue of rats in the
micronuclei assay (46) after i.p. exposure to AFB,, so, with this
mode of administration, it is possible that unmetabolized AFB,
could reach bone marrow cells. AFB, is also carcinogenic in
extrahepatic tissues: it induces carcinomas at low incidence in
the glandular stomach (10) and fibrosarcomas are inducible at
the site of injection when AFB, is given several times in doses
of 50 and 500 /tg subcutaneously (12). However, the absence
of mutagenic activity after oral application most likely is due to
the efficient activation of AFB, in the liver, where the chemical
is converted to the ultimate carcinogen, the reactive 2,3-oxide
(20), in a single, cytochrome P-450-dependent step and interacts
mainly at sites where these enzymes are accumulated. Accor-
dingly, no reactive gene-mutation inducing metabolites are ex-
pected to reach the granulation tissue.
In contrast to AFB,, 2-AAF and 2-AF are activated by an at
least two step, cytochrome P-450-dependent mono-oxygenase
process (22,51): in the case of 2-AAF this includes a deacetyl-
ation step (47). Both aromatic amines can be metabolized by ram
seminal vesicles to species mutagenic in in vitro bacterial tests
(45). The conversion of 2-AF to a gene-mutation inducing species
in the Granuloma Pouch Assay agrees with these facts. In vitro
2-AF can be co-oxidized by the PHS-pathway (7) to products
mutagenic in bacterial tests (8). The acetylated aromatic amine,
however, can be less readily metabolized by peroxidative
processes (38). A low deacetylase activity of the granulation
tissue, in contrast to bladder tissue for instance (39), could explain
the absence of mutagenic activity after direct exposure.
From data obtained after oral administration, we conclude that
unlike 2-AF, 2-AAF may be converted into a fairly stable species
by JV-hydroxylation; thus reaching the granulation tissue. There,
the hypothetical stable intermediate could be converted to the
actual mutagen by A'.O-acetyltransferases or sulphotransferases
(1). The formation of this intermediate was increased when two
intraperitoneal administrations preceeded the single administration
by gavage (Figure 1): a stimulation of phase two conjugation
reactions, or alternatively the overloading of detoxifying enzyme
systems might be the reason. Using the micronucleus test in rats,
2-AAF dosed via oral gavage gave a weak positive response (4),
but failed to induce a significantly increased number of
micronuclei after i.p. application (52). It is possible that this mode
of administration prevents the formation of a liver mediated,
stable 2-AAF intermediate.
The involvement of cytochrome P-450-dependent mono-
oxygenases in the metabolism of VCM (25,21) and in the
formation of mutagenic metabolites in short term mutagenicity
tests has been well documented (3,5,13). The mutagenic activity
of VCM by direct exposure of the granulation tissue might be
due to the reactive monomer per se: this molecule is lipophilic
and probably membrane active. Thus, it could stimulate
phospholipid turnover, and subsequently its own PHS mediated
metabolic conversion. No data from other laboratories are
available to support this hypothesis.
The non-linear dose-response relationship obtained with VCM
can be explained by a non-proportional VCM concentration and
a sensitive subpopulation. The observed rapid disappearance of
the monomer probably due to rapid binding at the surrounding
tissue or polymerization (Figure 2), might be further stimulated
with increasing exposure levels. The concept of a small sensitive
target population is supported by the enhanced mutation
frequences found after exposure to VCM in a fraction of the
freshly isolated granulation tissue cells showing enhanced aldrin
epoxidase activity (Table I).
In conclusion, data obtained in the Granuloma Pouch Assay
demonstrate that in extrahepatic tissues in vivo hepatocarcinogens
can be converted to metabolites which are able to induce gene-
mutations. In the light of the reported mutagenic activity also
of benzo[a]pyrene (BP) (32) and 2-arnino-3-methylimidazo[4,5-./]-
quinoline (IQ) (44) in the Granuloma Pouch Assay, we propose
that a co-oxidation pathway is involved, since both of these
chemicals can be activated by prostaglandin H synthase-dependent
pathways (BP: 37,50; IQ: 53). The highest reported induced
mutation frequencies in the Granuloma Pouch Assay of these
chemicals are summarized in Figure 3. Clearly, using the
Granuloma Pouch Assay, the mutagenic potency of chemicals
known to be activated by the PHS pathway in vitro or ex vivo,
can be demonstrated in vivo.
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